Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

3423 - Symptomatic skeletal related events (SSE) and SSE-free-survival in real world castration-resistant prostate cancer (CRPC) patients: results from CAPRI

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Supportive Care and Symptom Management

Tumour Site

Prostate Cancer

Presenters

Malou Kuppen

Citation

Annals of Oncology (2018) 29 (suppl_8): viii271-viii302. 10.1093/annonc/mdy284

Authors

M. Kuppen1, H.M. Westgeest2, A.J.M. van den Eertwegh3, J. Van Moorselaar4, N. Mehra5, I. van Oort6, A.C.M. van den Bergh7, J..L. Coenen8, K.K.H. Aben9, R. Somford10, J. Lavalaye11, A. Bergman12, C.A. Uyl-de Groot13, W.R. Gerritsen5

Author affiliations

  • 1 Institute For Medical Technology Assessment, Erasmus School of Health Policy and Management, 3062 PA - Rotterdam/NL
  • 2 Medical Oncology, Amphia Ziekenhuis, 4819 EV - Breda/NL
  • 3 Medical Oncology, Vrije University Medical Centre (VUMC), 1081 HV - Amsterdam/NL
  • 4 Urology, Vrije University Medical Centre (VUMC), 1081 HV - Amsterdam/NL
  • 5 Medical Oncology, Radboud University Medical Centre Nijmegen, 6500 HB - Nijmegen/NL
  • 6 Urology, Radboud University Medical Centre Nijmegen, 6500 HB - Nijmegen/NL
  • 7 Radiation oncology, UMCG, Groningen/NL
  • 8 Medical Oncology, Isala Klinieken, 8025 AB - Zwolle/NL
  • 9 Iknl, Comprehensive cancer centre, Nijmegen/NL
  • 10 Urology, Canisius Wilhelmina Ziekenhuis, Nijmegen/NL
  • 11 Nuclear Medicine, Antonius Ziekenhuis, Nieuwengein/NL
  • 12 Division Of Internal Medicine (mod) And Oncogenomics, Division of Internal Medicine (MOD) and Oncogenomics, 1066CX - Amsterdam/NL
  • 13 Institute Of Health Policy & Management  , Institute for Medical Technology Assessment, Erasmus University, 3062 PA - Rotterdam/NL
More

Resources

Abstract 3423

Background

Bone metastases are common in CRPC patients and these patients (pts) are at risk for symptomatic skeletal related events (SSE). Bone directed therapy and early initation of a life-prolonging drug (LPD) therapy can prevent or prolong time to SSEs. The objective is to evaluate whether delay in LPD has adverse outcome in CRPC pts and a shorter SSE-free interval.

Methods

CAPRI is an investigator-initiated, observational study in 20 hospitals in the Netherlands. All treated CRPC pts are retrospectively included in subgroups based on type of first line treatment: LPD (docetaxel, abiraterone, enzalutamide or radium-223) or non-LPD (other drugs as anti-androgens, prednisone). SSEs are defined as the occurrence of either radiotherapy (RT) to the bone, surgery to the bone, pathological fracture or spinal cord compression (SCC).

Results

1,618 pts were included in this analysis. Median follow-up was 26 months (IQR 15-39). 466 (29%) were treated with LPD (mostly docetaxel 15%) and 1,152 (71%) with non-LPD (mostly bicalutamide 62%) in first line. In the non-LPD subgroup, LPD was postponed in 712 patients. The LPD subgroup had frequent bone metastases, worse ECOG and, higher LDH, ALP and PSA at the start of first line therapy. 36% of all patients experienced a SSE during follow-up (32% RT to the bone, 4% surgery to the bone, 4% pathological fracture and 6% SCC). There was a small difference in total SSEs between subgroups (39% for LPD vs 35% for non-LPD, p = 0.064). Median SSE-free survival was 13.0 vs 21.2 months for LPD and non-LPD respectively (HR 1.626, p = 0.007). Correction for prognostic factors showed that type of first line therapy (LPD/non-LPD) was not associated with SSE-free survival (HR 1.021, p = 0.817). Worse ECOG and presence of bone metastases were significant predictors for worse SSE-free survival.

Conclusions

Approximately 40% of CRPC-patients developed a SSE during follow-up. Worse patient and disease characteristics probably influenced timing of LPD. These factors were also related with worse SSE-free survival. Delay in the initiation of a LPD at castration-resistant state does not appear to influence outcome related to time-to-SSE.

Clinical trial identification

The CAPRI study is registered in the Dutch Trial Registry as NTR3591.

Legal entity responsible for the study

Institute for Medical Technology Assessment, Erasmus University Rotterdam.

Funding

The CAPRI registry was funded by Sanofi-Aventis Netherlands B.V., Janssen-Cilag B.V., Astellas Pharma B.V., and Bayer B.V. The funding organizations had no role in the design and conduct of the study, collection, management, analysis, interpretation of the data, and preparation, review, or approval of the abstract.

Editorial Acknowledgement

Disclosure

A.J.M. van den Eertwegh: Study grant, travel expenses ASCO: Sanofi. Speaker fee, advisory board: Astellas. J. Van Moorselaar: Receipt of grants/research supports: Astellas, Ferring, Ipsen; Honoraria, consultation fees: Amgen, Astellas, AstraZeneca, Bayer, Janssen, Sanofi-Genzyme. I. van Oort: Conflict of interest: Astellas, Janssen, Sanofi, Bayer. J.L. Coenen: Advisory board: Sanofi. A. Bergman: PI of one of the IIS sponsored by Sanofi. W.R. Gerritsen: Speaker fees: Astellas, Bavarian Nordic, Bristol-Myers Squibb, MSD, Janssen-Cilag; Advisory boards: Amgen, Astellas, Bayer, Bristol-Myers Squibb, Curevac, Dendreon, Janssen-Cilag, Merck (MSD), Morphosys, Sanofi; Ad hoc consultancy: Aglaia Biomedical Ventures, Psioxus Therapeutics. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.